endovascular.es

Título: Proxy Biomedical announces facility expansion
Fecha: 21-12-2015
Galway, Ireland, December 21st, 2015 – Proxy Biomedical Ltd., a leading global innovator in the design, development and manufacturing of biomaterial based product solutions for medical implants, today announced a substantial facility expansion. Over the last twelve months, the company launched a series of innovative product solutions, to address unmet needs in key markets and support growing customer requirements. The expansion is a direct result of new business, and continued revenue growth, supported by the recent launch of these new solutions.
Early this year, the company expanded its range of resorbable and non-resorbable biomaterial solutions for vascular indications. The company is now a leading supplier of PTFE encapsulation for stents, in addition to offering a range of biomaterial coating solutions for structural heart implants, as well as occlusion and retrieval devices.
Proxy also launched Proxy Bio-XT, a unique proprietary process that reinforces resorbable implants for applications such as soft tissue fixation in Sports Medicine and Orthopaedics. In April, the company released ProTEX Med polypropylene, a custom synthesized resin with a unique FDA Master File reference. The material will be used for manufacturing implantable textiles, facilitating the approval process for products, such as hernia mesh, used in General Surgery.
To accommodate these additional technologies and services and to meet growing demand, Proxy Biomedical is undergoing a substantial facility expansion, which is due for completion in Q2 2016. The company will double cleanroom manufacturing facilities, introducing a suite of new technologies and biomaterial conversion processes.
“It has been an exciting year for Proxy Biomedical, as we have expanded our technology portfolio and enhanced both our facility and our team, to better accommodate market needs and the growing demand for our product solutions,” said Peter Mulrooney, Chief Executive Officer. “We continue to see substantial year on year revenue growth and we look forward to maintaining this momentum in the years ahead.”
Looking forward to 2016, Proxy Biomedical expects to expand its solutions portfolio for resorbable biomaterials, in both textiles and solid implants. Pre-clinical trials are scheduled to evaluate innovative antimicrobial implantable materials, while the company’s coating capabilities are set for further expansion, to accommodate an ever greater range of indications.
About Proxy Biomedical Limited
Proxy Biomedical Ltd. is an Irish based company that specializes in biomaterial product solutions for medical implantable devices, with a proven track record in innovative design and quality-assured manufacturing. The company offers a full-service solution, from the design and development of key components, to finished devices for world leading tier-one medical device companies who seek a trusted partner to help realise their product development needs. Proxy Biomedical Ltd. is quality assured to ISO 13485:2012 and FDA standards, including certification for the provision of Design Services.
Media Contact:
Stephen Duffy
Stephen.duffy@proxybiomedical.com
Tel: +353 91 896941
Fuente: endovascular.es

endovasculares.es